<p>在 12 月 18 日，隨着美國總統唐納德·特朗普簽署行政命令重新分類娛樂性藥物並放寬相關限制，像 Canopy Growth (CGC)、Tilray Brands (TLRY) 和 Cronos Group (CRON) 這樣的 cannabis 股票大幅上漲。</p>
<h3>享受 TipRanks Premium 50% 折扣，放心投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
<p>特朗普的命令將大麻重新分類為第三類藥物，降低了其之前的第一類藥物地位。其他第一類藥物包括沒有被接受的醫療用途的高度上癮藥物，如海洛因。較低級別的第三類藥物被認為具有較低的濫用潛力，例如含有可待因的泰諾。</p>
<p>特朗普對大麻的重新分類被視為期待已久的里程碑。然而，行政命令並未允許合法的娛樂性銷售。在白宮的一個儀式上，特朗普強調該行政命令並不合法化大麻，並且他 “絕不認可其作為娛樂性藥物的使用”。</p>
<h2><strong>放寬大麻限制</strong></h2>
<p>在行政命令簽署儀式上，特朗普和美國公共衞生官員表示，重新分類將使研究人員更容易研究大麻的影響及其潛在的醫療益處。</p>
<p>儘管如此，許多總部位於加拿大的美國上市大麻公司的股票在重新分類的消息傳出後上漲了 3% 到 6%。該行業已經等待多年以便在美國重新分類大麻並放寬其使用限制。與此同時，交易員和投資者在很大程度上放棄了大麻股票。AdvisorShares 大麻 ETF 自 2021 年以來已下降超過 85%。</p>
<h2><strong>TLRY 股票值得購買嗎？</strong></h2>
<p>Tilray 的股票在三位華爾街分析師中獲得了一致的中等買入評級。該評級基於過去三個月內的兩項買入和一項賣出建議。TLRY 的平均目標價為 7.00 美元，意味着從當前水平有 44.75% 的下行空間。</p>

CRON

TLRY

<p>大麻股票如 CGC、TLRY 和 CRON 在特朗普總統簽署行政命令將大麻重新分類為第三類藥物後大幅上漲，此舉放寬了限制但並未合法化娛樂性使用。重新分類旨在促進對大麻醫療益處的研究。儘管股票上漲，AdvisorShares 大麻 ETF 自 2021 年以來已下跌超過 85%。Tilray 股票的評級為適度買入，價格目標暗示有 44.75% 的下行空間</p>

<p>Cannabis stocks such as Canopy Growth (CGC), Tilray Brands (TLRY), and Cronos Group (CRON) are up sharply on Dec. 18 after U.S. President Donald Trump signed an executive order to reschedule the recreational drug and ease restrictions around it.</p>
<div class="lb-trans"><p>在 12 月 18 日，隨着美國總統唐納德·特朗普簽署行政命令重新分類娛樂性藥物並放寬相關限制，像 Canopy Growth (CGC)、Tilray Brands (TLRY) 和 Cronos Group (CRON) 這樣的 cannabis 股票大幅上漲。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，放心投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
</div><p>Trump's order reclassifies cannabis as a Schedule III drug, lowering it from its previous Schedule I status. Other Schedule I substances include highly addictive drugs with no accepted medical use, such as heroin. Lower level Schedule III substances are considered to have reduced potential for abuse such as Tylenol with Codeine in it.</p>
<div class="lb-trans"><p>特朗普的命令將大麻重新分類為第三類藥物，降低了其之前的第一類藥物地位。其他第一類藥物包括沒有被接受的醫療用途的高度上癮藥物，如海洛因。較低級別的第三類藥物被認為具有較低的濫用潛力，例如含有可待因的泰諾。</p>
</div><p>Trump's reclassification of cannabis is being applauded as a long-awaited milestone. However, the executive order stops short of permitting legalized recreational sales of the drug. In a White House ceremony, Trump stressed that the executive order doesn't legalize cannabis and that he &#34;in no way sanctions its use as a recreational drug.&#34;</p>
<div class="lb-trans"><p>特朗普對大麻的重新分類被視為期待已久的里程碑。然而，行政命令並未允許合法的娛樂性銷售。在白宮的一個儀式上，特朗普強調該行政命令並不合法化大麻，並且他 “絕不認可其作為娛樂性藥物的使用”。</p>
</div><h2><strong>Easing of Cannabis Restrictions</strong></h2>
<div class="lb-trans"><h2><strong>放寬大麻限制</strong></h2>
</div><p>In the executive order signing ceremony, Trump and U.S. public health officials said that the reclassification would enable researchers to more easily study the effects of cannabis and its potential medical benefits.</p>
<div class="lb-trans"><p>在行政命令簽署儀式上，特朗普和美國公共衞生官員表示，重新分類將使研究人員更容易研究大麻的影響及其潛在的醫療益處。</p>
</div><p>Still, U.S.-listed shares of cannabis companies, many of which are based in Canada, rose between 3% and 6% on news of the reclassification. The industry has waited years for cannabis to be reclassified in the U.S. and restrictions around its use eased. In the meantime, traders and investors have largely abandoned cannabis stocks. The AdvisorShares cannabis ETF has declined more than 85% since 2021.</p>
<div class="lb-trans"><p>儘管如此，許多總部位於加拿大的美國上市大麻公司的股票在重新分類的消息傳出後上漲了 3% 到 6%。該行業已經等待多年以便在美國重新分類大麻並放寬其使用限制。與此同時，交易員和投資者在很大程度上放棄了大麻股票。AdvisorShares 大麻 ETF 自 2021 年以來已下降超過 85%。</p>
</div><h2><strong>Is TLRY Stock a Buy?</strong></h2>
<div class="lb-trans"><h2><strong>TLRY 股票值得購買嗎？</strong></h2>
</div><p>The stock of Tilray has a consensus Moderate Buy rating among three Wall Street analysts. That rating is based on two Buy and one Sell recommendations issued in the last three months. The average TLRY price target of $7.00 implies 44.75% downside from current levels.</p>
<div class="lb-trans"><p>Tilray 的股票在三位華爾街分析師中獲得了一致的中等買入評級。該評級基於過去三個月內的兩項買入和一項賣出建議。TLRY 的平均目標價為 7.00 美元，意味着從當前水平有 44.75% 的下行空間。</p>
</div>

CGC, TLRY, CRON: Cannabis Stocks Soar as Trump Reclassifies the Drug

Canopy Growth、Tilray Brands、Cronos：隨着特朗普重新分類該藥物，Cannabis 股票大漲